Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study.

BACKGROUND

Valoctocogene roxaparvovec, an adeno-associated virus vector that transfers a human factor (F)VIII (FVIII) coding sequence to hepatocytes, provides bleeding protection for people with severe hemophilia A.

OBJECTIVES

Determine the efficacy and safety of valoctocogene roxaparvovec with concomitant prophylactic glucocorticoids in the open-label, single-arm, phase 3b GENEr8-3 trial.

METHODS

Participants with severe hemophilia A who were using hemophilia A prophylaxis received one 6 × 1013 vg/kg infusion of valoctocogene roxaparvovec concomitantly with daily prophylactic glucocorticoids (40 mg prednisolone equivalent/d weeks 0-8; taper to 5 mg/d weeks 9-19). The primary efficacy endpoint was change from baseline in FVIII activity (chromogenic substrate assay) at week 52. Secondary efficacy endpoints included annualized rate of FVIII use and annualized bleeding rate for treated bleeds. Safety was assessed by adverse events (AEs). Analysis populations were intent-to-treat (ITT; received valoctocogene roxaparvovec) for safety analyses and modified ITT (≥52 FVIII infusions in the year before dosing) for efficacy analyses.

RESULTS

Overall, 22 participants with severe hemophilia A received valoctocogene roxaparvovec. In the modified ITT population (n = 21), mean week 52 FVIII activity increased from baseline (imputed as 1 IU/dL) to 16.1 IU/dL (SD, 22.4; P = .0057); posthemophilia A prophylaxis, mean treated annualized bleeding rate and mean annualized FVIII use decreased 67.1% and 91.6% from baseline, respectively (P < .05). The most common AE was alanine aminotransferase elevation (20/22 participants). Glucocorticoid-related AEs occurred in 19 of 22 participants. No participants discontinued the study.

CONCLUSION

Based on cross-trial comparisons, prophylactic glucocorticoids do not confer safety or efficacy benefits compared with reactive glucocorticoid regimens.